One study (in US claims data) also aimed to replicate ARISTOTLE [33,34] and, in contrast to our study, found superiority for apixaban for stroke/SE, which may be linked to population differences such as lower TTR in US patients on warfarin [35] and differences in ethnicity. Here, TTR is linked to Stroke.